Journals / Ulusal Travma ve Acil Cerrahi Dergisi / 2010 / Cilt: 16 - Sayı: 1

Deneysel sepsiste IgM ile zenginleştirilmiş immünglobulin ve sıvı replasman tedavisininin sinir ileti hızına olan etkileri

Effects of IgM-enriched immunoglobulin and fluid replacement on nerve conduction velocity in experimental sepsis

Pages
9–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There is a need to clarify the mechanisms of action with further randomized, clinical and experimental trials.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:BACKGROUND Neuromuscular abnormalities in sepsis, termed critical illness polyneuropathy (CIP), have been suggested to be induced by inflammatory mechanisms and/or relative hypovolemia.
📊
Key Findings & Data:RESULTS There was no statistically significant difference in NCV levels within and among the Sham-operated, colloidand IVIG-treated groups.
💡
Conclusion & Impact:There is a need to clarify the mechanisms of action with further randomized, clinical and experimental trials.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

BACKGROUND Neuromuscular abnormalities in sepsis, termed critical illness polyneuropathy (CIP), have been suggested to be induced by inflammatory mechanisms and/or relative hypovolemia. CIP is characterized by early electrophysiological findings before the clinical symptoms. This study aimed to investigate the effect of intravenous immunoglobulin (IVIG) and volume replacement therapies on the possible nerve conduction velocity (NCV) alterations in the early phase of experimental sepsis. METHODS Forty-six Sprague-Dawley rats were randomly assigned to four groups. Cecal ligation/perforation was performed to induce experimental sepsis. NCV was assessed in the tail nerve. RESULTS There was no statistically significant difference in NCV levels within and among the Sham-operated, colloidand IVIG-treated groups. In the sepsis without treatment group, there was a statistically significant decrease in NCV levels. CONCLUSION NCV is decreased in the early stage of experimental sepsis and it may be accepted as an early electrophysiological sign in CIP. Treatment with either IgM-enriched IVIG or early volume replacement appears to prevent the decrease in NCV in the early phase of experimental sepsis. Results were statistically indistinguishable between the IVIG- and colloid-treated groups. No statistical difference between these groups is noteworthy. There is a need to clarify the mechanisms of action with further randomized, clinical and experimental trials.

Özet

AMAÇ Sepsiste yoğun bakım polinöropatisi (YBP) olarak adlandırılan nöromusküler ileti bozukluklarının erken dönemde enflamatuvar mekanizmalar ve/veya rölatif hipovolemi ile tetiklendiği ileri sürülmektedir. YBP, klinik bulgulardan önce erken dönemde beliren elektrofizyolojik bulgularla kendini gösterir. Çalışmamızda, IVIG ve volüm replasman tedavisinin deneysel sepsisin erken fazında görülebilen sinir ileti hızındaki (SİH) değişikliklere olan etkisinin araştırılması amaçlandı. GEREÇ VE YÖNTEM Randomize olarak 46 Spraque-Dawley sıçan çalışmaya dahil edildi. Deneysel sepsis çekal ligasyon ve perforasyon ile oluşturuldu. SİH, kuyruk sinirindeki ölçümlerle değerlendirildi. BULGULAR Sham grubu, kolloid grubu ve IVIG grubunda hem grup içinde hem de gruplar arasında SİH’nın değişimi açısından anlamlı fark olmadığı görüldü. Herhangi bir tedavinin uygulanmadığı sepsis grubunda ise; SİH’nın başlangıç değerine göre anlamlı azaldığı görüldü. SONUÇ YBP’nin erken elektrofizyolojik bir bulgusu olarak kabul edilebilen SİH sepsisin erken döneminde azalmaktadır. Deneysel sepsisin erken döneminde görülen SİH’deki azalmanın IgM ile zenginleştirilmiş IVIG verilmesi ile veya erken yapılan volüm replasmanı ile önlenebileceği görülmektedir. IVIG tedavisi uygulanan grupla kolloidle erken volüm replasmanı uygulanan grup arasındaki sonuçların istatistiksel olarak farklı olmaması dikkat çekici olarak değerlendirilmiş ve konu ile ilgili mekanizmanın açığa çıkması için randomize klinik ve deneysel çalışmalara ihtiyaç olduğu kanısına varılmıştır.

🔖

Cite This Article

ÇANKAYALI, İ., DOĞAN, Y. H., SOLAK, İ., ERİŞ, O., DEMİRGÖREN, S., MORAL, A. R. (2010). Deneysel sepsiste IgM ile zenginleştirilmiş immünglobulin ve sıvı replasman tedavisininin sinir ileti hızına olan etkileri. Ulusal Travma ve Acil Cerrahi Dergisi, Cilt: 16 - Sayı: 1, 9–14. https://ajindex.com/articles/324276

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry 1984;47:1223-31
  2. Bolton CF, Young GB, Zochodne DW. The neurological complications of sepsis. Ann Neurol 1993;33:94-100
  3. Bolton CF. Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996;24:1408-16
  4. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32:140-63
  5. Tennilä A, Salmi T, Pettilä V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med 2000;26:1360-3
  6. Cankayali I, Dogan YH, Solak I, Demirag K, Eris O, Demirgoren S, et al. Neuromuscular deterioration in the early stage of sepsis in rats. Crit Care 2007;11:R1
  7. Druschky A, Herkert M, Radespiel-Tröger M, Druschky K, Hund E, Becker CM, et al. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001;27:686-93
  8. Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997;23:1144-9
  9. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142:1-11
  10. Hughes RA, Raphaël JC, Swan AV, Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2004;(1):CD002063
  11. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62
  12. Van den Berg-Vos RM, Franssen H, Visser J, de Visser M, de Haan RJ, Wokke JH, et al. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment. J Neurol 2002;249:330-6
  13. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-9
  14. Pul R, Nguyen D, Schmitz U, Marx P, Stangel M. Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin Neuropharmacol 2002;25:254-9
  15. Otero-Antón E, González-Quintela A, Lóp